Compare PCSA & JWEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCSA | JWEL |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.5M |
| IPO Year | 2012 | 2020 |
| Metric | PCSA | JWEL |
|---|---|---|
| Price | $2.41 | $2.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | ★ 39.3K | 9.0K |
| Earning Date | 05-07-2026 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.11 | $1.47 |
| 52 Week High | $8.88 | $2.98 |
| Indicator | PCSA | JWEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 57.17 |
| Support Level | $0.21 | $2.02 |
| Resistance Level | $2.56 | $2.51 |
| Average True Range (ATR) | 0.33 | 0.09 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 25.41 | 78.39 |
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Jowell Global Ltd is a cosmetics, health, nutritional supplements, and household products e-commerce platform in China. The company offers its branded products to customers and also sells and distributes products from other companies on its platform. In addition, it allows third parties to open their stores on its platform for a service fee based on their sales revenues generated from their online stores and provides them with information about market needs, enabling them to manage their sales effort, as well as an effective platform to promote their brands. The company currently operates under four sales channels: Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing. Geographically, it generates all of its revenue from the PRC.